

Zachary

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5239846/publications.pdf>

Version: 2024-02-01

21
papers

43
citations

2258059

3
h-index

1872680

6
g-index

21
all docs

21
docs citations

21
times ranked

103
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3433-3439.	5.2	5
2	Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2021, 11, a035477.	6.2	2
3	Laboratory evaluation of folate deficiency among inpatients with cancer. <i>International Journal of Laboratory Hematology</i> , 2021, 43, O164-O167.	1.3	0
4	Outcomes of adult T-Cell leukemia/lymphoma with allogeneic stem cell transplantation: single-institution experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2177-2183.	1.3	2
5	Molecularly targeted therapies for relapsed and refractory peripheral T-cell lymphomas. <i>Seminars in Hematology</i> , 2021, 58, 78-84.	3.4	2
6	Selective STAT3 Degradation Dissects Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens. <i>Blood</i> , 2021, 138, 865-865.	1.4	0
7	TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy. <i>Blood</i> , 2021, 138, 1367-1367.	1.4	2
8	Inpatient folate testing at an academic cancer center: single-year experience. <i>Supportive Care in Cancer</i> , 2020, 28, 4235-4240.	2.2	2
9	Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 18-20.	1.4	3
10	Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study. <i>Blood</i> , 2020, 136, 11-12.	1.4	6
11	Impact of Additional Cytogenetic Abnormalities and Complex Karyotype on Event-Free Survival in Acute Promyelocytic Leukemia: Analysis from a Single Academic Center Plus the APML4 Study. <i>Blood</i> , 2020, 136, 34-35.	1.4	0
12	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. <i>Leukemia Research</i> , 2019, 82, 19-23.	0.8	0
13	De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes. <i>Blood</i> , 2019, 134, 2708-2708.	1.4	2
14	RAS Mutations Are Independently Associated with Decreased Overall Survival and Event-Free Survival in Patients with AML Receiving Induction Chemotherapy. <i>Blood</i> , 2019, 134, 18-18.	1.4	8
15	Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience. <i>Blood</i> , 2019, 134, 2850-2850.	1.4	1
16	Dual Driver Mutant BCR-ABL1-Negative Myeloid Neoplasms: Multicenter Clinicopathologic and Genomic Analysis. <i>Blood</i> , 2019, 134, 4173-4173.	1.4	0
17	Widespread use of measurable residual disease in acute myeloid leukemia practice. <i>Leukemia Research</i> , 2018, 67, 92-98.	0.8	6
18	Loss of Plasmacytoid Dendritic Cell Differentiation Is Highly Predictive for Persistent Measurable Residual Disease and Poor Outcomes in Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1523-1523.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Molecular Predictors and Current Management of Minimal Residual Disease (MRD) Following Induction Chemotherapy for Acute Myeloid Leukemia (AML). Blood, 2018, 132, 292-292.	1.4	1
20	Folate Testing and Deficiency in Hospitalized Cancer Patients. Blood, 2018, 132, 5814-5814.	1.4	0
21	Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies. Leukemia and Lymphoma, 0, , 1-13.	1.3	1